ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last2,881 to 2,900 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)93 of 1,264

77 of 1,279

1.3 points

-0.6 to 3.3

2,543NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI77 of 1,264

68 of 1,279

0.8 points

-1.0 to 2.6

2,543NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Death (Cardiac, Vascular, Non-cardiovascular)10 of 1,264

11 of 1,279

-0.1 points

-0.8 to 0.7

2,543NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Target Vessel Myocardial Infarction (TV-MI)71 of 1,264

56 of 1,279

1.2 points

-0.5 to 3.0

2,543NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced All Death/All MI80 of 1,264

72 of 1,279

0.7 points

-1.2 to 2.6

2,543NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With All Coronary Revascularization54 of 1,264

39 of 1,279

1.2 points

-0.2 to 2.7

2,543NCT02173379

Absorb IV Randomized Controlled Trial

Dabigatran 150 mg vs Warfarin: serious adverse events165 of 1,273

150 of 1,266

1.1 points

-1.5 to 3.7

2,539NCT00291330

Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism

Absorb BVS vs XIENCE: Number of Participants With Repeat Coronary Arteriography71 of 1,259

87 of 1,270

-1.2 points

-3.1 to 0.7

2,529NCT02173379

Absorb IV Randomized Controlled Trial

Transdisciplinary Approach vs Multidisciplinary Approach: Dispensing of Psychotropic Medications161 of 742

315 of 1,787

4.1 points

0.7 to 7.6

2,529NCT03442322

Optimizing Care for Patients With Dementia

Absorb BVS vs XIENCE: Number of Participants With Target Vessel Revascularization (TVR)22 of 1,255

20 of 1,273

0.2 points

-0.8 to 1.2

2,528NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)98 of 1,255

83 of 1,273

1.3 points

-0.7 to 3.3

2,528NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced Death/All MI/All Revascularization (DMR)125 of 1,255

114 of 1,273

1.0 points

-1.3 to 3.3

2,528NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Myocardial Infarction (MI)80 of 1,255

65 of 1,273

1.3 points

-0.6 to 3.1

2,528NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With ID-TVR Excluding TLR22 of 1,255

20 of 1,273

0.2 points

-0.8 to 1.2

2,528NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)102 of 1,255

89 of 1,273

1.1 points

-0.9 to 3.2

2,528NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With All Coronary Revascularization64 of 1,255

51 of 1,273

1.1 points

-0.5 to 2.8

2,528NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Target Lesion Failure (TLF)98 of 1,255

83 of 1,273

1.3 points

-0.7 to 3.3

2,528NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced All Death/All MI89 of 1,255

79 of 1,273

0.9 points

-1.1 to 2.8

2,528NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI83 of 1,255

73 of 1,273

0.9 points

-1.0 to 2.8

2,528NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)111 of 1,255

101 of 1,273

0.9 points

-1.3 to 3.1

2,528NCT02173379

Absorb IV Randomized Controlled Trial

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=145"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=145

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02173379-7c14a724",
        "title": "Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)",
        "summary": "93 of 1264 against 77 of 1279; risk difference 1.3 points, 95% interval -0.6 to 3.3; NCT02173379, Absorb IV Randomized Controlled Trial",
        "record": "/library/comparisons/NCT02173379-7c14a724",
        "nct_id": "NCT02173379",
        "kind": "outcome",
        "participants": 2543,
        "risk_difference": {
          "value": 0.013372665551607765,
          "lower": -0.006119210315356283,
          "upper": 0.03300900186362439
        },
        "group_1": "93 of 1,264",
        "group_2": "77 of 1,279",
        "difference": "1.3 points",
        "interval": "-0.6 to 3.3",
        "trial_title": "Absorb IV Randomized Controlled Trial"
      },
      {
        "id": "NCT02173379-b82ddd81",
        "title": "Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI",
        "summary": "77 of 1264 against 68 of 1279; risk difference 0.8 points, 95% interval -1.0 to 2.6; NCT02173379, Absorb IV Randomized Controlled Trial",
        "record": "/library/comparisons/NCT02173379-b82ddd81",
        "nct_id": "NCT02173379",
        "kind": "outcome",
        "participants": 2543,
        "risk_difference": {
          "value": 0.007751185162458804,
          "lower": -0.010388179075993272,
          "upper": 0.02600914219221606
        },
        "group_1": "77 of 1,264",
        "group_2": "68 of 1,279",
        "difference": "0.8 points",
        "interval": "-1.0 to 2.6",
        "trial_title": "Absorb IV Randomized Controlled Trial"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=146",
  "request_id": "AerknHzhXiVAuzA0"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?